May 7, 2008 Savient Reports Favorable Interim Data from Puricase® Open Label Extension Study April 21, 2008 Savient Provides Update on  Puricase® BLA February 4, 2008 Savient Reports Additional Positive Phase 3 Results for Puricase® December 13, 2007 Savient Press Release - Successful Phase 3 Trials of Puricase® October 16, 2007 Savient Completes Puricase® Phase 3 Study March 6, 2007 Savient Completes Enrollment for Puricase® Phase 3 Study August 4, 2006 Savient Completes Rosemont Sale June 14, 2006 Savient Initiates Patient Dosing for Puricase® Phase 3 Study May 3, 2006 Savient Receives FDA Final Approval for Puricase® March 21, 2006 Savient and FDA Agree on Phase 3 Protocol SPA Puricase® (PEG-uricase) on Track to Enter Phase 3 November 14, 2005 Savient's Puricase® (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients with Treatment Resistant Gout July 28, 2005 Savient Pharmaceuticals Meets with FDA for End-of-Phase 2 Review of Puricase® May 12, 2005 Savient Reports Positive Top-Line Results for Puricase® Phase 2 Trial January 10, 2005 Savient Pharmaceuticals, Inc. Completes Patient Dosing in Phase II Clinical Trial of Puricase for Severe Gout July 7, 2003 Savient Pharmaceuticals, Inc. Successfully Completes Phase I Clinical Study of Puricase® for Severe Gout August 17, 1998 Bio-Technology General Acquires Rights to Technology for Important New Drug, PEG-Uricase, from Duke University and Mountain View Pharmaceuticals, Inc.